Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hyperlipidemia Overview 9 Therapeutics Development 10 Pipeline Products for Hyperlipidemia - Overview 10 Pipeline Products for Hyperlipidemia - Comparative Analysis 11 Hyperlipidemia - Therapeutics under Development by Companies 12 Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 16 Hyperlipidemia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Hyperlipidemia - Products under Development by Companies 21 Hyperlipidemia - Products under Investigation by Universities/Institutes 25 Hyperlipidemia - Companies Involved in Therapeutics Development 26 Acasti Pharma Inc. 26 Allergan Plc 27 Alnylam Pharmaceuticals, Inc. 28 Amgen Inc. 29 Arbutus Biopharma Corporation 30 Arisaph Pharmaceuticals, Inc. 31 Astellas Pharma Inc. 32 AstraZeneca Plc 33 BASF SE 34 BCWorld Pharm Co. Ltd. 35 Cadila Pharmaceuticals Ltd. 36 Cardax Pharmaceuticals, Inc. 37 Catabasis Pharmaceuticals, Inc. 38 CJ HealthCare Corp. 39 CymaBay Therapeutics, Inc. 40 Daewoong Pharmaceutical Co., Ltd. 41 Daiichi Sankyo Company, Limited 42 Esperion Therapeutics, Inc. 43 HanAll Biopharma Co., Ltd. 44 Hanmi Pharmaceuticals, Co. Ltd. 45 Huons Co., Ltd. 46 Hyundai Pharmaceutical Co., Ltd. 47 Innovent Biologics, Inc. 48 Jeil Pharmaceutical Co., Ltd. 49 Kowa Company, Ltd. 50 LG Life Science LTD. 51 Lotus Pharmaceutical Co., Ltd. 52 Pfizer Inc. 53 Pharmena SA 54 Prometheon Pharma, LLC 55 Protalix BioTherapeutics, Inc. 56 Sancilio & Company, Inc. 57 Thetis Pharmaceuticals LLC 58 Yuhan Corporation 59 Zydus Cadila Healthcare Limited 60 Hyperlipidemia - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 73 (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 73 (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 74 (atorvastatin calcium + losartan potassium) - Drug Profile 75 (atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 76 (candesartan + rosuvastatin calcium) - Drug Profile 77 (gemigliptin + rosuvastatin calcium) - Drug Profile 78 (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 79 AEM-28 - Drug Profile 80 AEM-2802 - Drug Profile 81 AEM-2814 - Drug Profile 82 ALN-AC3 - Drug Profile 83 ALN-ANG - Drug Profile 84 ARI-3037MO - Drug Profile 85 AS-1708727 - Drug Profile 86 BCWPC-001 - Drug Profile 87 bempedoic acid - Drug Profile 88 bezafibrate ER - Drug Profile 90 BH-03004 - Drug Profile 91 BioE-1115 - Drug Profile 92 bococizumab - Drug Profile 93 BSN-272 - Drug Profile 94 CAT-2000 Series - Drug Profile 95 CAT-2003 - Drug Profile 96 CDX-085 - Drug Profile 97 centatin - Drug Profile 99 DS-8312 - Drug Profile 100 DWJ-1330 - Drug Profile 101 DWJ-1351 - Drug Profile 102 etanercept biosimilar - Drug Profile 103 evolocumab - Drug Profile 104 gemcabene calcium - Drug Profile 107 HOB-071 - Drug Profile 108 HU-012 - Drug Profile 109 IBI-306 - Drug Profile 110 icosabutate - Drug Profile 111 ISIS-APOCIIILRx - Drug Profile 112 JLP-1302 - Drug Profile 113 JLP-1401 - Drug Profile 114 K-312 - Drug Profile 115 leucine + niacin - Drug Profile 116 MAT-9001 - Drug Profile 117 MBX-8025 - Drug Profile 118 NKPL-66 - Drug Profile 120 Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 122 omega-3-carboxylic acids - Drug Profile 123 PF-06427878 - Drug Profile 125 PF-06815345 - Drug Profile 126 pitavastatin CR - Drug Profile 127 Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 128 saroglitazar - Drug Profile 129 SC-401 - Drug Profile 130 Small Molecule for Hyperlipidemia - Drug Profile 131 Small Molecule for Hypertriglyceridaemia - Drug Profile 132 Small Molecule for Hypertriglyceridemia - Drug Profile 133 Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 134 Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 135 Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 136 Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 137 TKM-HTG - Drug Profile 139 TKMApoC-3 - Drug Profile 140 TP-101 - Drug Profile 141 TRIA-662 - Drug Profile 142 volanesorsen sodium - Drug Profile 144 YH-22189 - Drug Profile 146 Hyperlipidemia - Recent Pipeline Updates 147 Hyperlipidemia - Dormant Projects 190 Hyperlipidemia - Dormant Projects 190 Hyperlipidemia - Discontinued Products 198 Hyperlipidemia - Product Development Milestones 199 Featured News & Press Releases 199 Appendix 207 Methodology 207 Coverage 207 Secondary Research 207 Primary Research 207 Expert Panel Validation 207 Contact Us 207 Disclaimer 208

List of Tables Number of Products under Development for Hyperlipidemia, H1 2016 14 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Comparative Analysis by Unknown Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Development by Companies, H1 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2016 29 Hyperlipidemia - Pipeline by Acasti Pharma Inc., H1 2016 30 Hyperlipidemia - Pipeline by Allergan Plc, H1 2016 31 Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 32 Hyperlipidemia - Pipeline by Amgen Inc., H1 2016 33 Hyperlipidemia - Pipeline by Arbutus Biopharma Corporation, H1 2016 34 Hyperlipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 35 Hyperlipidemia - Pipeline by Astellas Pharma Inc., H1 2016 36 Hyperlipidemia - Pipeline by AstraZeneca Plc, H1 2016 37 Hyperlipidemia - Pipeline by BASF SE, H1 2016 38 Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 39 Hyperlipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2016 40 Hyperlipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 41 Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 42 Hyperlipidemia - Pipeline by CJ HealthCare Corp., H1 2016 43 Hyperlipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 44 Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 45 Hyperlipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46 Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2016 47 Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 48 Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 49 Hyperlipidemia - Pipeline by Huons Co., Ltd., H1 2016 50 Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 51 Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H1 2016 52 Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 53 Hyperlipidemia - Pipeline by Kowa Company, Ltd., H1 2016 54 Hyperlipidemia - Pipeline by LG Life Science LTD., H1 2016 55 Hyperlipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 56 Hyperlipidemia - Pipeline by Pfizer Inc., H1 2016 57 Hyperlipidemia - Pipeline by Pharmena SA, H1 2016 58 Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H1 2016 59 Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 60 Hyperlipidemia - Pipeline by Sancilio & Company, Inc., H1 2016 61 Hyperlipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 62 Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2016 63 Hyperlipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 64 Assessment by Monotherapy Products, H1 2016 65 Assessment by Combination Products, H1 2016 66 Number of Products by Stage and Target, H1 2016 68 Number of Products by Stage and Mechanism of Action, H1 2016 71 Number of Products by Stage and Route of Administration, H1 2016 74 Number of Products by Stage and Molecule Type, H1 2016 76 Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2016 151 Hyperlipidemia - Dormant Projects, H1 2016 194 Hyperlipidemia - Dormant Projects (Contd..1), H1 2016 195 Hyperlipidemia - Dormant Projects (Contd..2), H1 2016 196 Hyperlipidemia - Dormant Projects (Contd..3), H1 2016 197 Hyperlipidemia - Dormant Projects (Contd..4), H1 2016 198 Hyperlipidemia - Dormant Projects (Contd..5), H1 2016 199 Hyperlipidemia - Dormant Projects (Contd..6), H1 2016 200 Hyperlipidemia - Dormant Projects (Contd..7), H1 2016 201 Hyperlipidemia - Discontinued Products, H1 2016 202 List of Figures Number of Products under Development for Hyperlipidemia, H1 2016 14 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Products, H1 2016 23 Assessment by Monotherapy Products, H1 2016 65 Assessment by Combination Products, H1 2016 66 Number of Products by Top 10 Targets, H1 2016 67 Number of Products by Stage and Top 10 Targets, H1 2016 67 Number of Products by Top 10 Mechanism of Actions, H1 2016 70 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 70 Number of Products by Routes of Administration, H1 2016 73 Number of Products by Stage and Routes of Administration, H1 2016 73 Number of Products by Molecule Types, H1 2016 75 Number of Products by Stage and Molecule Types, H1 2016 75

Acasti Pharma Inc. Allergan Plc Alnylam Pharmaceuticals, Inc. Amgen Inc. Arbutus Biopharma Corporation Arisaph Pharmaceuticals, Inc. Astellas Pharma Inc. AstraZeneca Plc BASF SE BCWorld Pharm Co. Ltd. Cadila Pharmaceuticals Ltd. Cardax Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc. CJ HealthCare Corp. CymaBay Therapeutics, Inc. Daewoong Pharmaceutical Co., Ltd. Daiichi Sankyo Company, Limited Esperion Therapeutics, Inc. HanAll Biopharma Co., Ltd. Hanmi Pharmaceuticals, Co. Ltd. Huons Co., Ltd. Hyundai Pharmaceutical Co., Ltd. Innovent Biologics, Inc. Jeil Pharmaceutical Co., Ltd. Kowa Company, Ltd. LG Life Science LTD. Lotus Pharmaceutical Co., Ltd. Pfizer Inc. Pharmena SA Prometheon Pharma, LLC Protalix BioTherapeutics, Inc. Sancilio & Company, Inc. Thetis Pharmaceuticals LLC Yuhan Corporation Zydus Cadila Healthcare Limited